Investing.com - Financial Markets Worldwide

Provectus Biopharmaceuticals Inc (PVCT)

OTC Markets
Currency in USD
0.08694
-0.00186(-2.09%)
Closed·
PVCT Scorecard
Full Analysis
Suffers from weak gross profit margins
PVCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.079200.08900
52 wk Range
0.066100.15166
Key Statistics
Edit
Prev. Close
0.0888
Open
0.08405
Day's Range
0.0792-0.089
52 wk Range
0.0661-0.15166
Volume
54.55K
Average Volume (3m)
186.21K
1-Year Change
5.21%
Book Value / Share
-0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PVCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 7
Short term obligations exceed liquid assets
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Provectus Biopharmaceuticals Inc Company Profile

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company’s lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and blood cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
6
Market
United States

Compare PVCT to Peers and Sector

Metrics to compare
PVCT
Peers
Sector
Relationship
P/E Ratio
−6.9x0.0x−0.5x
PEG Ratio
0.070.010.00
Price/Book
−7.3x0.0x2.6x
Price / LTM Sales
56.7x1.3x3.3x
Upside (Analyst Target)
-267.5%42.9%
Fair Value Upside
Unlock12.1%6.2%Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-- / --
Revenue / Forecast
278.63K / --
EPS Revisions
a
a
Unlock
Last 90 days

PVCT Income Statement

FAQ

What Stock Exchange Does Provectus Trade On?

Provectus is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Provectus?

The stock symbol for Provectus is "PVCT."

What Is the Provectus Market Cap?

As of today, Provectus market cap is 34.48M.

What Is Provectus's Earnings Per Share (TTM)?

The Provectus EPS (TTM) is -0.01.

From a Technical Analysis Perspective, Is PVCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Provectus Stock Split?

Provectus has split 0 times.

How Many Employees Does Provectus Have?

Provectus has 6 employees.

What is the current trading status of Provectus (PVCT)?

As of 12 Aug 2025, Provectus (PVCT) is trading at a price of 0.09, with a previous close of 0.09. The stock has fluctuated within a day range of 0.08 to 0.09, while its 52-week range spans from 0.07 to 0.15.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.